© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
July 14, 2019
No differences were observed in the magnitude of ubrogepant treatment effect between defined triptan subgroups.
July 13, 2019
Atogepant significantly reduced mean monthly migraine days compared to placebo across a number of doses and was generally well-tolerated, with no treatment-related serious adverse events.
May 07, 2019
A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.
October 23, 2018
ITI-214 showed favorable safety with early signs of improvement in motor symptoms for patients with Parkinson disease